Evidence types
Basic science articles covering early-stage IBD research, disease mechanisms, lab findings, microbiome work, genetics, and experimental models.
Page 1 of 15 · 707 articles
MSC therapy and its interaction with autophagy could point to new ways to boost cell-based treatments for IBD. For people with Crohn's disease or ulcerative colitis, this could eventually lead to different therapeutic...
The paper describes a plant-derived polysaccharide that reduced inflammation, improved barrier proteins, and shifted gut microbiota in a mouse model of ulcerative colitis—mechanisms relevant to IBD. If replicated and...
A formulation that targets and sustains budesonide release in the intestine could improve local anti-inflammatory effects and reduce systemic exposure compared with standard oral formulations. If translational studies...
The study identifies a TSPO-targeting compound (koumine) that improved disease and intestinal barrier function in mouse models of ulcerative colitis and links the effect to changes in energy metabolism—an emerging area...
The study suggests a specific mechanism—modulation of the SphK1/S1P/NF-κB pathway—by which components of a traditional herbal formula may reduce intestinal inflammation and influence the gut microbiome. If validated in...
The paper points to a specific RNA-modifying protein (YTHDF2) that appears to drive inflammatory signaling and pyroptotic cell death in lab models of ulcerative colitis; targeting this pathway could open new avenues for...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Molecular...
The study identifies a prebiotic-encapsulated extracellular vesicle approach that reduced colitis severity and early kidney stress in a mouse model, pointing to the gut microbiota and barrier function as key mediators....
The endoplasmic reticulum helps control cell metabolism and is implicated in conditions including metabolic disorders, cancer, and inflammatory diseases such as Crohn’s disease.
AHR signaling may influence epithelial inflammation in IBD and could be a potential target for future therapies or biomarker research. Findings are preliminary but point to IL‑8 as a responsive inflammatory mediator in...
The study describes a new small-molecule approach that reduced inflammation in mouse models of ulcerative colitis by targeting NF-κB transcription (p65 G-quadruplex). That suggests a potential future drug pathway...
This study describes a new preclinical approach to reduce inflammation in IBD by degrading NLRP3 rather than merely inhibiting it. For people following IBD therapeutic research, degraders could offer longer-lasting...
The paper reports a preclinical targeted-delivery formulation that may allow lower systemic exposure to tofacitinib while concentrating drug in inflamed colon tissue—potentially reducing known systemic risks of JAK...
The study suggests two different ways to reduce inflammation in a mouse model of ulcerative colitis—one using a plant-derived compound that shifts beneficial microbes and metabolites, the other using an antibiotic that...
The study points to creatine metabolism and CKB as regulators of intestinal epithelial health and shows hucMSC-derived vesicles can restore metabolic balance and reduce inflammation in preclinical models—highlighting a...
The study presents a single engineered probiotic that can detect intestinal inflammation and, when reprogrammed, deliver IL‑22‑Fc locally to promote mucosal healing in animal models — a potential future avenue for...
The study suggests a specific immune pathway (NOX2-driven ROS in M1-like macrophages) by which colitis can worsen periodontitis, pointing to a potential therapeutic target that could eventually benefit people with IBD...
Findings suggest a dietary-derived prebiotic (Poria cocos polysaccharides) may reduce experimental colitis by shifting the microbiome and bile acids toward anti-inflammatory signaling—an avenue that could inform future...
Reliable, low‑cost lab methods to measure mesalazine in tablets help ensure pharmaceutical quality and correct dosing of 5‑ASA drugs used in ulcerative colitis and IBD.
This study tests a novel method to deliver healthy mitochondria to the gut lining and reports improved cellular energy, barrier function, and decreased oxidative stress in a mouse model of ulcerative colitis—suggesting a...
This study maps gene and microRNA changes linked to ulcerative colitis and tests how deleting STAT6 or treating mice with Corylus avellana extract shifts those molecular signatures. Identifying such molecular players may...
If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...
A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...
The study suggests postbiotics from a gut bacterium can reduce inflammation in a mouse colitis model and identifies a candidate metabolite and signaling pathway that could be targeted in future IBD research.
The findings describe a novel cell‑based IL‑10 delivery strategy that reduced experimental colitis and altered gut microbiota—an approach that could inform future IBD therapies research.
The work helps explain why people with IBD often have unstable gut microbiomes and limited recovery of beneficial bacteria, linking those patterns to inflammation — which is relevant for efforts to develop...
The study identifies a botanical extract that reduced colitis severity in mice and pinpoints the PI3K/Akt/FOXO3A pathway as a possible mechanism — a potential starting point for new therapeutic research relevant to...
The review evaluates a revised preprint linking GM-CSF, macrophages, and ILC-like cells in Crohn’s disease using human spatial transcriptomics and zebrafish experiments. It highlights limitations that matter because they...
This review connects enteric sensory neuron dysfunction to symptoms common in IBS and IBD (pain, diarrhea, constipation, dysmotility). Understanding IPAN plasticity could point to new treatment targets that act locally...
Findings suggest a dietary flavonoid (daidzein) may reduce colitis in mice via microbial activation and host signaling pathways, pointing toward microbiome-informed nutritional approaches for IBD.
Identifying genes and pathways involved in IBD can point to new biological mechanisms, potential biomarkers, and future targets for research that may eventually inform diagnosis or treatment.
The review identifies berberine as a potential adjunct therapy for UC because it may target both gut microbes and epithelial inflammasome-mediated cell death, processes important in disease activity and barrier function.
This study reports that an optimized Cycas revoluta leaf extract reduced colon inflammation and markers of oxidative stress in a rat model of ulcerative colitis, suggesting it could be a source of bioactive compounds...
The paper identifies a metabolic pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to epithelial injury in ulcerative colitis and proposes quercetin as a candidate inhibitor—potentially...
This study identifies KCTD10 as a regulator of intestinal stem cell function and mucosal repair in experimental colitis, which could point to new mechanistic insights about why epithelial healing fails in some cases of...
The study identifies a redox–inflammasome pathway (Nrf2 linked to NLRP3/IL‑1β) relevant to UC and shows that sulforaphane can modulate this axis in intestinal epithelial cells, highlighting a potential therapeutic target...
The gut microbiome and its metabolic pathways are areas of active research in IBD; this study suggests specific genera and predicted functions that could become candidate biomarkers or targets for follow-up studies.
Researchers engineered bispecific antibodies that block two inflammatory pathways (TL1A and IL-12/23p40) simultaneously, a strategy that could overcome limits of single-target therapies in IBD. The work is preclinical...
The study identifies how secreted products from Lactobacillus brevis can selectively lower inflammatory gene expression in an intestinal epithelial cell model, pointing to microbiome-derived mechanisms that might become...
The study links microbiome metabolites to reduced epithelial inflammation and improved barrier function via AhR and cholinergic pathways—mechanisms relevant to IBD. This could guide future preclinical and therapeutic...
This work suggests a new experimental target (extracellular vimentin) that reduced inflammation, fibrosis-related markers, and necroptotic cell-death markers in mice and in cultured colon cells — processes that are...
People with ulcerative colitis may eventually have an oral small-molecule option that targets the TNF-α pathway instead of injectable biologics. Early-stage preclinical work suggests a new mechanism (allosteric MKK3...
If validated, differences in tissue QDPR could become a marker to help differentiate UC from CD and to indicate mucosal antioxidant/repair status, which may be relevant for disease monitoring and research into new...
This preclinical study suggests a plant extract reduced inflammation and oxidative stress in a mouse model of ulcerative colitis and proposes molecular targets — an early step toward potential new treatments or research...
Researchers identified a plant-derived compound that reduced inflammation, oxidative stress, and gut dysbiosis in a mouse model of ulcerative colitis; this could point to new mechanistic leads for future therapies...
The study identifies a new monocyte-surface RNA (Y RNAs) that appears higher in an exploratory IBD cohort and amplifies inflammatory signalling in cells and mice, which could point to new biomarker or therapeutic...
The paper points out that reused patient records and preprocessing choices can change how well gene-expression models appear to predict infliximab response. That matters because such biases could mislead researchers and...
This preclinical study suggests clarithromycin may reduce colon inflammation in ulcerative colitis models and identifies Kv1.3 and the Th17/Treg balance as possible mechanisms — findings that could guide future...
